Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R. Vitale MG, et al. Among authors: spada m. PLoS One. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. eCollection 2018. PLoS One. 2018. PMID: 29979712 Free PMC article.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group. De Giorgi U, et al. BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23. BJU Int. 2019. PMID: 29956884 Free article.
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Caffo O, Frantellizzi V, Tucci M, Galli L, Monari F, Baldari S, Masini C, Bortolus R, Facchini G, Alongi P, Agostini S, Zichi C, Biasco E, Fanti S, Pignata S, Filice A, Borsatti E, Rossetti S, Spada M, Cortesi E, De Vincentis G. Caffo O, et al. Among authors: spada m. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2633-2638. doi: 10.1007/s00259-020-04796-w. Epub 2020 Apr 5. Eur J Nucl Med Mol Imaging. 2020. PMID: 32249345
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra.
Caffo O, Frantellizzi V, Monari F, Galli L, Costa RP, Pinto C, Tucci M, Baldari S, Facchini G, Bortolus R, Alongi F, Alongi P, Donner D, Fanti S, Sbrana A, Morabito A, Masini C, Zichi C, Pignata S, Borsatti E, Salgarello M, Spada M, De Giorgi U, Lo Re G, Cortesi E, De Vincentis G. Caffo O, et al. Among authors: spada m. Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25. Cancer Biother Radiopharm. 2021. PMID: 33769088
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
Bersanelli M, Verzoni E, Cortellini A, Giusti R, Calvetti L, Ermacora P, Di Napoli M, Catino A, Guadalupi V, Guaitoli G, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Perrone F, Maruzzo M, Rossi E, Casadei C, Montesarchio V, Grossi F, Rizzo M, Travagliato Liboria MG, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Camerini A, Sorarù M, Zucali PA, Ricciardi S, Russo A, Negrini G, Banzi MC, Lacidogna G, Fornarini G, Laera L, Mucciarini C, Santoni M, Mosillo C, Bonetti A, Longo L, Sartori D, Baldini E, Guida M, Iannopollo M, Bordonaro R, Morelli MF, Tagliaferri P, Spada M, Ceribelli A, Silva RR, Nolè F, Beretta G, Giovanis P, Santini D, Luzi Fedeli S, Nanni O, Maiello E, Labianca R, Pinto C, Clemente A, Tognetto M, De Giorgi U, Pignata S, Di Maio M, Buti S, Giannarelli D; FICOG group (Federation of Italian Cooperative Oncology Groups). Bersanelli M, et al. Among authors: spada m. EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37434748 Free PMC article.
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
Murianni V, Signori A, Buti S, Rebuzzi SE, Bimbatti D, De Giorgi U, Chiellino S, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Milella M, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Di Napoli M, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Roviello G, Catalano F, Damassi A, Cremante M, Rescigno P, Fornarini G, Banna GL. Murianni V, et al. Among authors: spada m. Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024. Front Oncol. 2024. PMID: 38410103 Free PMC article.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: spada m. Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12. Future Oncol. 2024. PMID: 38682738
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: spada m. Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960. Online ahead of print. Future Oncol. 2024. PMID: 38861289
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Maiorano BA, Catalano M, Mercinelli C, Roviello G, Maruzzo M, De Giorgi U, Chiellino S, Sbrana A, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Napoli MD, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Puglisi S, Signori A, Necchi A, Banna GL, Fornarini G, Buti S, Rebuzzi SE. Maiorano BA, et al. Among authors: spada m. Clin Genitourin Cancer. 2024 Nov 10;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39603144
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Di Bartolomeo M, et al. Among authors: spada m. Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5. Target Oncol. 2018. PMID: 29582224
777 results